Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

Fig. 2

Meta-analyses on the association of preoperative bevacizumab treatment with parenchymal damage and posthepatectomy liver failure in patients with CLM. a Association of bevacizumab treatment with sinusoidal obstruction syndrome (SOS). b Association of bevacizumab treatment with hepatic fibrosis. c Association of bevacizumab treatment with posthepatectomy liver failure

Back to article page
\